Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NGM BIOPHARMACEUTICALS, INC.

(NGM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. The CompanyÔÇÖs product candidates include NGM282, NGM313, NGM386, NGM395, NGM120, NGM217 and NGM621. NGM282 is an engineered variant of the human hormone known as FGF19, which the Company is developing for the treatment of non-alcoholic steatohepatitis (NASH). NGM313 is an agonistic antibody selectively activating fibroblast growth factor receptor 1c-beta-klotho and has the potential as an insulin sensitizer for the treatment of type two diabetes and NASH. NGM386 and NGM395 are engineered variants of the human hormone known as GDF15, which is developed for the treatment of obesity. NGM120 is an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, and cancer.

Number of employees : 210 people.
Sales per Business
20192020Delta
Novel Therapeutics103.54100%87.37100% -15.62%
USD in Million
Sales per region
20192020Delta
United States103.54100%87.37100% -15.62%
USD in Million
Managers
Name Title Age Since
David J. Woodhouse, Dr. Chief Executive Officer & Director 49 2020
Siobhan Nolan Mangini CFO & Principal Accounting Officer 39 2020
Hui Tian, Dr. Vice President-Research - 2013
Marc Learned, Dr. Vice President-Research Operations - -
Jin-Long Chen, Dr. Director & Chief Scientific Officer 57 2014
Hsiao Dee Lieu, Dr. Chief Medical Officer & Senior Vice President 49 2019
Valerie L. Pierce Chief Compliance Officer, SVP & General Counsel 57 2019
David V. Goeddel, Dr. Lead Independent Director 68 2018
Mark Leschly Independent Director 51 2008
Suzanne Sawochka Hooper Independent Director 54 2018
Members of the board
Name Title Age Since
William J. Rieflin Executive Chairman 60 2018
David V. Goeddel, Dr. Lead Independent Director 68 2018
Mark Leschly Independent Director 51 2008
Jin-Long Chen, Dr. Director & Chief Scientific Officer 57 2014
David J. Woodhouse, Dr. Chief Executive Officer & Director 49 2020
Suzanne Sawochka Hooper Independent Director 54 2018
Shelly Guyer Independent Director 59 2019
Carole Ho Independent Director 47 2020
Roger M. Perlmutter, Dr. Director 67 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 77,018,206 54,182,060 70.3% 0 0.0% 70.3%
Shareholders
NameEquities%
The Column Group LLC 17,993,932 23.4%
Merck & Co., Inc. 12,955,016 16.8%
Prospect Venture Partners 4,925,000 6.39%
Topspin Management LLC 4,833,333 6.28%
Rho Ventures 3,766,666 4.89%
William J. Rieflin 2,772,535 3.60%
Redmile Group LLC 2,751,815 3.57%
The Vanguard Group, Inc. 2,184,809 2.84%
Point72 Asset Management LP 2,175,000 2.82%
Tichenor Ventures LLC 1,872,314 2.43%
Company contact information
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
South San Francisco, CA 94080-7014

Phone : +1.650.243.5555
Web : http://www.ngmbio.com
Sector Bio Therapeutic Drugs